The latest Business updates from the science industry
by Heather Hobbs Robotic labs to supercharge UK infection research activities
The Infection Innovation Consortium iiCON, led by Liverpool School of Tropical Medicine (LSTM), has received a £10 million UK government investment to develop large Category Three robotic laboratories capable of handling a range of dangerous and deadly pathogens. The award is part of the Liverpool City Region Life Sciences Investment Zone plans to supercharge the sector. Overall, the Investment Zone plans to create 8,000 new jobs and potentially deliver £800 million of public and private investment over 10 years.
Professor Janet Hemingway, founding director of iiCON commented: “As a consortium, iiCON brings together leading UK organisations in infection R&D – including the world-renowned expertise and facilities at Liverpool School of Tropical Medicine. This combined capability and focus on co-innovation has enabled the consortium to secure funding to support the progression of this innovative development.”
The new labs, which will be located in the Liverpool Life Sciences Accelerator Building in the city’s investment zone, are expected to complete in two years. “The project will involve the refurbishment and upgrade of existing Category 2 laboratories to validated and operational Category 3 containment level laboratories. LSTM has the largest number of Category 3 laboratories in the North West and we already work with a wide range of pathogens in these laboratories. In our new labs, we will be operating with the same pathogens, in an expanded highly-secure facility.”
Expanding further on the build programme Professor Hemingway told International Labmate “We will be going out to tender for a specialist main contractor and design consultants later this year, alongside a specialist technical team to specify and design the technology within the facility. We are also building a specialist team to run and manage the technology within the labs post-completion and expect this to create around 80 to 100 new posts.
“As far as we are aware, this will be the fi rst Category Three Robotic laboratory in the UK, so the design process will involve specifying and developing bespoke technological solutions for our enhanced requirements. We will also be looking at technology used in existing Category 2 robotic laboratories to explore what modifi cations would be needed to implement this technology in a Category 3 setting.
“We are developing a strategic working group with industry leaders who currently operate Category 2 robotic laboratories. This will enable mutual knowledge sharing of both past experience and our current learnings as we design and set up this facility – helping to facilitate best practice and support wider industry progression and innovation in this space.”
When operational, the new facilities will enable iiCON to increase the commercialisation of two of its R&D platforms led by LSTM: Organoids and its Bio-Actives library which together have the potential to shape the next generation of transformative novel antimicrobial products and therapies.
In addition, and also as part of the Investment Zone plans, iiCON and LSTM will develop RIBA Stage 2 plans for a new facility alongside Pembroke House, a research and development, innovation and education hub in Liverpool’s Knowledge Quarter. This specialist biotech and Category 3 laboratory space, will provide increased specialist biotech and high-containment Category Three laboratories to house the expansion of iiCON’s existing R&D platforms.
“From the outset, iiCON was structured to develop innovative R&D platforms using cutting-edge technology and approaches that would allow companies to bring their products through to market more effectively,” Professor Hemingway said.
Professor Janet Hemingway Work being conducted at some of LSTM’s R&D labs
“We’re pleased to have secured this important funding as part of the Liverpool City Region Life Sciences Investment Zone programme. This funding is an important next step which will enable us to continue to develop and expand our operational pipeline - opening out our highly specialist offering to industry partners of all sizes to support their innovation and save and improve lives worldwide.
“Over the next fi ve to ten years, we anticipate signifi cant growth in the numbers of direct high-level jobs associated with the intermediate and long- term developments outlined in the prospectus, alongside support for local business growth in this area.
“As a place-based initiative, our location in the heart of the Liverpool City Region’s thriving health and life sciences ecosystem has been key to the success of the programme. The region has world-leading capability in drug discovery, diagnostics, clinical trials, & vaccine manufacturing capability within one of Europe’s largest biopharmaceutical manufacturing clusters and the plans laid out in the Investment Zone prospectus speak to the scale of the ambition within the region.”
Mayor of the Liverpool City Region, Steve Rotheram, said: “With up to £800 million of investment and thousands of quality, high skilled jobs on offer, the Liverpool City Region Innovation Zone is an important tool in our arsenal to position our area at the head of UK science and innovation.
“But in the Liverpool City Region, we’re proud to do things differently. Throughout the development of our Innovation Zone, I have been clear that any investment in our area must go further than purely fi nancial incentives. I want to use our status as a force for good, to connect our residents up to secure, well-paid jobs and training opportunities and attract transformational investment into our communities.
“Becoming an innovation superpower is a lofty ambition – but I fi rmly believe that, if anywhere has the potential to achieve it, then it is the Liverpool City Region.”
More information online:
ilmt.co/PL/Wln6 62603pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148
